Datasets:

---

Recag

/

Rp_CommonC_477

like 0

ERROR: type should be string, got "https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUuc3RhZ2luZy5tZWRzY2FwZS5jb20vYXJ0aWNsZS8yODcyMzAtb3ZlcnZpZXc=\nDrugs & Diseases > Psychiatry\nTardive Dystonia\nAuthor: Daniel Schneider, MD, MA; Chief Editor: Randon S Welton, MD more...\nSections Tardive Dystonia\nDeterrence/Prevention\nDopamine-depleting agents\nAtypical antipsychotics (serotonin dopamine receptor antagonists)\nAnticholinergic agents\nAcetylcholine receptor inhibitors\nTardive dystonia is a form of tardive dyskinesia. It is a movement disorder characterized by involuntary muscle contractions caused primarily by taking dopamine receptor blockers like antipsychotic medications.\nTardive dystonia starts insidiously and progresses over months or years, until it becomes static. Dystonia typically presents in a twisting pattern with deviations on multiple anatomical planes. The movements typical of tardive dystonia are generally slower and more sustained than other dyskinesias.\nSymptoms of dystonia can range from very mild to severe. Dystonia can affect different body parts, and often the symptoms of dystonia progress through stages. Some early symptoms include:\na \"dragging leg\"\ncramping of the foot\ninvoluntary pulling of the neck\nuncontrollable blinking\nSee Clinical Presentation for more detail.\nThere is no single test to confirm the diagnosis of dystonia. To differentiate tardive dystonia from all causes of dystonia, base the workup on the history findings and clinical presentation of the dystonic movements.\nA routine evaluation may include the following:\nCBC count with peripheral smear\nThyroid hormone indices\nCalcium level\nMagnesium level\nLiver enzyme values\nAntinuclear antibody level\nVDRL test\nHIV antibody titer\nSerum, copper, and ceruloplasmin values\nElectroencephalogram, CT scan, or MRI of the brain\nSee Workup for more detail.\nThe first step after the diagnosis of tardive dystonia induced by neuroleptics or other drugs is to taper and then discontinue the causative drugs. Many times, a severe psychiatric illness makes this impossible, but carefully reconsidering the indications for dopamine antagonists in a given patient and considering alternate therapy are imperative. Switching these patients to antipsychotic medications, like clozapine, with less potent dopamine blockade may be considered. [1] Unfortunately, it is not uncommon for the symptoms to worsen for a time after the offending medication is discontinued or reduced.\nA recently introduced treatment is botulinum toxin which is injected into the affected muscle. There it blocks the effect of the chemical acetylcholine that produces muscle contractions. Consider botulinum toxin therapy if the dystonia is focal and amenable to the treatment.\nThe primary pharmacological treatment for tardive dystonia is dopamine-depleting agents. Another option would be dopamine receptor blockers (ie, neuroleptics). [2, 3, 4] However, 2013 guidelines from the American Academy of Neurology do not recommend the use of risperidone because it appears to cause tardive symptoms. [5] Instead, amantadine and tetrabenazine are recommended. A common observation for all tardive syndromes is that the symptoms improve with an increase of dopamine blockade and worsen with a decrease. Thus, the goal is to add a medication that will provide dopamine blockade while minimizing the risk of worsening the tardive syndrome or creating new tardive syndromes.\nDeep brain stimulation is probably the surgical treatment of choice at this time for those with severely disabling dystonia who have not responded to medical therapy.\nSee Treatment and Medication for more detail.\nDystonia is commonly defined as \"a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures.\" [6] Historically, the first use of the term was by Oppenheim in 1911, but earlier descriptions of the syndrome have been widely acknowledged. [7, 8]\nThe phenomenology of dystonia is remarkably variable. Differences in the extent and severity of muscle and frequency of symptom involvement range from intermittent contraction limited to a single body region to generalized dystonia involving the limbs and axial muscles. Features such as age of onset and presumed etiology play a tremendous role in prognosis and treatment. As such, a complete diagnosis of dystonia typically includes its characterization along three axes: age of onset, distribution, and presumed etiology. [7, 8]\nAge is generally divided into early onset (≤26 years) and late onset (>26 years), with a younger age of onset associated with a more generalized and severe course in primary dystonias.\nDistribution is divided into focal (a single part of the body affected), segmental (contiguous parts of the body affected), and generalized (the entire body affected). Terms such as multifocal (multiple noncontiguous body parts affected) and hemidystonia (an entire side of the body affected) are also used.\nAn abbreviated list of body parts commonly affected can include all four limbs, the trunk (pisa syndrome for a lateral deviation, camptocormia for a severe anterior flexion), the neck (torticollis for lateral rotation, anterocollis for anterior flexion, and posterocollis for posterior flexion), the jaw (mandibular dystonia or oromandibular dystonia), the tongue (lingual dystonia), the vocal cords (spasmodic dystonia), the larynx (laryngeal dystonia) or the eyelids (blepharospasm). Symptoms can occur intermittently, only with specific tasks (such as writer's cramp, embouchur dystonia or golf yips), or more chronically. In general, the more of the body involved, the worse the prognosis.\nThe etiology of dystonias typically divide into 4 broad categories: primary, dystonia-plus, heterodegenerative diseases with dystonia, and secondary dystonia. Primary dystonia is used for familial and nonfamilial genetic syndromes where dystonia is the major feature. A dystonia-plus syndrome is also a genetic syndrome with dystonia as the primary symptom but with other neurologic symptoms prominent (such as the dystonia-Parkinsonism or dystonia-myoclonus syndromes). This is in contrast to heterodegenerative diseases with dystonia when dystonia is present but not the major symptom (such as Wilson's disease or PKAN). Secondary dystonia is a dystonia brought on by an inciting event, such as a stroke, trauma, or drugs.\nTardive dystonia is a form of drug-induced secondary dystonia. Persistent dystonia was introduced by the French to describe the late complications of chlorpromazine therapy. In 1973, Keegan and Rajput introduced the term dystonia tarda to describe drug-induced sustained muscle spasm causing repetitive movements or abnormal postures in patients who were treated with levodopa. [9]\nToday, drug-induced dystonias are roughly divided into acute, chronic acute, and tardive. Acute dystonia is an immediate reaction to a drug treatment and chronic acute is the term used for continued symptoms with long-term treatment with an offending agent. In 1982, Burke et al coined the term tardive dystonia for dystonias that did not present as immediately after the introduction of the drug, but presented later and either continued or worsened after the drug's removal. [2] Tardive derives from the Latin word meaning late onset, and had already been used to describe abnormal orobuccal-lingual facial movements (ie, tardive dyskinesias) that also appeared as a late side effect to medications and tended to continue or worsen with the removal of the drugs.\nIn that paper, Burke and colleagues proposed the following four criteria for diagnosis:\nThe presence of chronic dystonia\nA history of antipsychotic drug treatment preceding or concurrent with the onset of dystonia\nThe exclusion of known causes of secondary dystonia by appropriate clinical and laboratory evaluation\nThe question of whether tardive dystonia should be considered a subset of tardive dyskinesia has been debated for a number of years. Grossly, there are many similarities. All tardive syndromes are caused by dopamine receptor blockers. They are all characterized by both their presentation days to months after the initial exposure and their continuation, or worsening, after the offending agent has been removed. However, in spite of these similarities, Burke et al suggested that tardive dystonia could be distinguished from the classic orobuccal-lingual choreic form of tardive dyskinesia not only by the dystonic nature of the involuntary movements but also by the frequency with which it causes significant neurologic disability. Burke et al noted that symptoms can begin after only a few weeks or a few days of exposure and the degree of improvement was much more limited compared with tardive dyskinesia. [2]\nOther writers have followed the lead of Burke and his colleagues, publishing reviews that point to the differences in clinical manifestations, prevalence, prognosis, and treatments between tardive dystonia and dyskinesia. [10, 3]\nThe pathophysiology of tardive dystonia is not well understood. Due to this limited understanding, it is helpful to briefly review what is known about the pathophysiology of dystonias in general to put this information in context.\nDystonia is considered to be a sign of basal ganglia dysfunction. One line of evidence for this is from the stroke and traumatic brain injury literature. Dystonia never occurs with pure cortical lesions and only develops after striatal lesions, sometimes occurring weeks or months after the inciting basal ganglia lesion.\nElectrophysiologically, dystonia is characterized by a sustained co-contraction of both agonist and antagonist muscles. Although most research has been done on primary focal dystonias, three areas of investigation have emerged in the literature. First, both EMG and imaging evidence shows a loss of reflex inhibition in spinal and brainstem reflexes and a loss of normal inhibitory patterns in the motor cortex. Second, there is evidence of abnormal cortical motor plasticity in patients with dystonia. Third, there is evidence of sensory processing abnormalities. Subtle impairment in spatial and temporal discrimination tasks as well as somatosensory evoked potentials are well documented. [7]\nThe pathophysiologic basis of tardive dystonia itself remains obscure. Why exposure to neuroleptics produces dystonia in some patients, chorea in some, and both in others is not clear.\nSachdev suggests that tardive dystonia may develop in individuals who are already vulnerable to dystonia, with the antipsychotic drugs activating a latent predisposition. [11]\nHowever, although primary dystonias and tardive dystonias have many similarities, they also have differences and some have been hesitant to conclude that these exist on a continuum with each other. In terms of genetic studies, the evidence for similar genetic mechanisms has been lacking. For example, in many families affected by idiopathic torsion dystonia, a mutation of the DYT1 gene on band 9q34 has been identified, but currently, no evidence exists that similar genetic factors cause the predisposition to tardive dystonia.\nFurther, the genetic evidence has been lacking that factors that predict tardive dyskinesia also predict tardive dystonia. For instance, the Ser9Gly polymorphism in the D3 receptor has been associated with vulnerability to tardive dyskinesia, but a study by Mihara et al looking at that gene and two other mutations known to cause decreased metabolism of neuroleptics through changes in cytochrome P4502D6 and a decreased baseline density number of D2 receptors, respectively, found no overrepresentation with any of these mutations and their sample of nine patients with tardive dystonia. [12] To date, no genetic markers have been identified that predict the development of tardive dystonia.\nThe neuropharmacology changes underlying tardive dystonia also remain poorly understood. Dopamine receptor blocking agents can cause an acute dystonic reaction that appears superficially similar to tardive dystonia. Two basic theories have emerged to explain this reaction: hypoactivity of dopamine system leading to an overactivity of acetylcholine activity, and a paradoxical hyperactivity of dopamine due to preferential blocking presynaptic receptors. There are studies that support both of these hypotheses; however, it is unclear how well this can generalize to tardive dystonia. For instance, although clinically anticholinergics can be used to treat tardive dystonia, they are far less effective than they are in acute drug-induced dystonias.\nOne theory has been proposed by Trugman et al, who maintained that repetitive stimulation of the D1 receptor by endogenous dopamine, resulting in sensitization of the D1-mediated striatal output in the presence of D2 receptor blockade, is a fundamental mechanism mediating tardive dyskinesia and tardive dystonia. [13] This hypothesis is based on a relative segregation of outputs; the D1-mediated striatal output is directed preferentially to the globus pallidus, internal segment and substantia nigra, and pars reticulata, and the D2-mediated output is directed preferentially to the globus pallidus and external segment.\nBy selectively blocking D2 receptors, long-term treatment with a conventional neuroleptic disrupts the normal, coordinated balance of D1- and D2-mediated striatal outputs. With long-term neuroleptic administration, endogenous dopamine is able to stimulate D1 receptors, whereas D2 receptors are occupied by neuroleptics.\nThe hypothesis that sensitization of the D1-mediated striatal output is involved in the pathogenesis is consistent with both the delayed onset of dystonia after neuroleptic initiation and the persistence of symptoms after neuroleptic withdrawal; therefore, this model predicts that the D1 antagonist will be beneficial in the treatment of tardive dystonia.\nThe major limitation to this theory is that it tries to conceptualize tardive dystonia and dyskinesia with a single pathway, yet the 2 disorders have differences in epidemiology, natural course, and treatment.\nYoung age, male sex, mental retardation, and electroconvulsive therapy have been identified as specific risk factors. Exposure to dopamine receptor blocking agents (DRBAs) is essential for the diagnosis of this disorder. Antipsychotic medications are the most significant etiologic factor. Other medications associated with tardive dystonia include antiemetics (eg, prochlorperazine, promethazine, metoclopramide) and antidepressants (eg, amoxapine). Also, single case reports for veralipride, a benzamide derivative, and lithium causing dystonia have been reported.\nAntipsychotic medications\nThe most common cause of tardive dystonia is exposure to antipsychotic medications (neuroleptics). Tardive dystonia develops in a shorter period and with significantly less total neuroleptic exposure than severe tardive dyskinesia. Also, patients with tardive dystonia seem to receive fewer doses of neuroleptic agents than persons who develop tardive dyskinesia.\nAll dopamine receptor antagonists that reportedly cause oral tardive dyskinesia also reportedly cause tardive dystonia. These include all first generation and second generation antipsychotic medications.\nThe duration of exposure to antipsychotic medications required to cause tardive dystonia ranges from months to years. Exposure to antipsychotics need not be long, and a minimum safe period is not apparent. This minimum duration of antipsychotic exposure seems to be shorter for women. A longer duration of exposure to antipsychotic medication does not correlate with the severity of dystonia; however, patients with generalized dystonia have shorter neuroleptic exposure than patients with focal dystonia.\nOther agents implicated in cases of tardive dystonia include amoxapine, an antidepressant with dopamine receptor–blocking properties, and antiemetics such as prochlorperazine, promethazine, and metoclopramide. [3]\nThe prevalence of tardive dystonia is 0.5-21.6% of patients who are treated with antipsychotic medications, with most on the lower end of that range. This condition undoubtedly is less common than oral-buccal-lingual tardive dyskinesia. In a survey of 555 psychiatric patients, Yassa et al found a prevalence rate of 34% for oral tardive dyskinesia and only 1.4% for tardive dystonia. [14] Similarly, Friedman et al found a prevalence rate of only 1.5% among 352 hospitalized psychiatric patients. [15] One study by Sethi et al indicated a prevalence rate of 21% for tardive dystonia among veterans institutionalized long-term. However, most of these cases were mild; only 20% were symptomatic. [16]\nTardive dystonia appears to occur in all ethnic and racial groups in which it has been studied. However, no large-scale prevalence studies have been done to determine its specific prevalence in each group.\nThe literature shows a higher prevalence in men than in women.\nIn 1982, Burke et al reported a 1.6:1 male-to-female preponderance ratio. In a follow-up of 107 patients, 16 of which had been previously followed by Burke, the ratio was 1.14:1. [2]\nFriedman et al [15] and Yassa et al [14] conducted studies of two unselected psychiatric populations, the results of which supported a male-to-female predominance ratio of 4:1 and 3:1, respectively.\nAlthough no large unselected population study exists, tardive dystonia appears to have an earlier mean age of onset than other related dystonic conditions.\nIn the study by Yassa et al, tardive dystonia had a mean age of onset of 40.5 years. [14] In a study by Kiriakakis et al of 107 patients with tardive dystonia, the mean age of onset was 38.3 +/- 13.7 years, with males having a younger age of onset then females (but also starting neuroleptics earlier). [4] It was also noted that the younger a patient's neuroleptic exposure, the shorter the interval before developing tardive dystonia.\nThe prognosis of patients with tardive dystonia is very poor. Unfortunately, once developed, this condition is usually persistent.\nThe discontinuation of all dopamine receptor antagonists appears to be the most important factor related to remission; patients who permanently discontinue these agents increase their chance of remission 4-fold compared with those patients who do not.\nAnother factor related to remission is the total duration of dopamine receptor antagonist therapy; patients taking dopamine receptor antagonists for less than 10 years have a 5-times higher chance of remission than those with more than 10 years of exposure.\nTardive dystonia is most likely permanent in patients who continue using neuroleptic drugs for more than 10 years. [4]\nThe indication for long-term use of dopamine receptor antagonists must be well established. Patients must be evaluated repeatedly in hopes of early detection of tardive dystonia; once tardive dystonia is present, the causative drug should be withdrawn if possible. If the patient is not disabled by dyskinesia, observing and hoping for a spontaneous recovery, rather than treating, is best.\nMortality/morbidity\nTardive dystonia causes pain and physical and emotional disability. Disability is moderate to severe in 70% of patients with tardive dystonia.\nDisabilities involve the activities of daily living and are socially embarrassing.\nImpairment of speech, vision, eating, sitting, and gait has been reported. Pain is also often an accompanying symptom. Any truncal or lower-limb dystonia causes a gait abnormality, leading to a bedridden state only in severe cases.\nThe social embarrassment and distress over the movements are the issues that often concern the patients most. Limitations (real or perceived) in keeping gainful employment and making new friends and romantic partners can be devastating. [3]\nPinninti NR, Faden J, Adityanjee A. Are Second-Generation Antipsychotics Useful in Tardive Dystonia?. Clin Neuropharmacol. 2015 Sep-Oct. 38 (5):183-97. [Medline].\nBurke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982 Dec. 32(12):1335-46. [Medline].\nAdityanjee, Aderibigbe YA, Jampala VC, Mathews T. The current status of tardive dystonia. Biol Psychiatry. 1999 Mar 15. 45(6):715-30. [Medline].\nKiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998 Nov. 121 (Pt 11):2053-66. [Medline].\nBhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30. 81(5):463-9. [Medline].\nFahn S, Marsden, CD, Calne DB. Classification and Investigation of Dystonia. Marsden CD, Fahn S. Movement Disorders, Vol. 2. London: Butterworths; 1987. 332-358.\nFahn, Stanley and Jankovic, Joseph. Principles and Practice of Movement Disorders. Philadelphia, PA: Churchill Livingston Elveiser; 2007.\nStacy, Mark A. Handbook of Dystonia. New York, NY: Informa Healthcare; 2007.\nKeegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst. 1973 Mar. 34(3):167-9. [Medline].\nKang UJ, Burke RE, Fahn S. Tardive dystonia. Adv Neurol. 1988. 50:415-29. [Medline].\nSachdev P. Risk factors for tardive dystonia: a case-control comparison with tardive dyskinesia. Acta Psychiatr Scand. 1993 Aug. 88(2):98-103. [Medline].\nMihara K, Kondo T, Higuchi H, Takahashi H, Yoshida K, Shimizu T. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet. 2002 Aug 8. 114(6):693-5. [Medline].\nTrugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord. 1994 Jul. 9(4):441-6. [Medline].\nYassa R, Nair V, Iskandar H. A comparison of severe tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand. 1989 Aug. 80(2):155-9. [Medline].\nFriedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry. 1987 Jun. 50(6):801-3. [Medline].\nSethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord. 1990. 5(4):319-21. [Medline].\nBurke RE. Neuroleptic-induced tardive dyskinesia variants. Lang AE, Weiner WJ, eds. Drug-Induced Movement Disorders. New York, NY: Futu; 1992. 168-98.\nvan Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull. 1999. 25 (4):741-8. [Medline].\nChase TN, Tamminga CA, Burrows H. Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia. Adv Neurol. 1988. 50:237-41. [Medline].\nArai N, Amano N, Iseki E, et al. Tardive dyskinesia with inflated neurons of the cerebellar dentate nucleus. Case reports and morphometric study. Acta Neuropathol (Berl). 1987. 73(1):38-42. [Medline].\nKaufman DM. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia. J Neuropsychiatry Clin Neurosci. 1994 Winter. 6(1):50-3. [Medline].\nHennings JM, Krause E, Bötzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1. 32(5):1167-71. [Medline].\nShapleske J, Mickay AP, Mckenna PJ. Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry. 1996 Apr. 168(4):516-8. [Medline].\nBlake LM, Marks RC, Nierman P, Luchins DJ. Clozapine and clonazepam in tardive dystonia. J Clin Psychopharmacol. 1991 Aug. 11(4):268-9. [Medline].\nTrottenberg T, Volkmann J, Deuschl G, Kühn AA, Schneider GH, Müller J. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology. 2005 Jan 25. 64(2):344-6. [Medline].\nZhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J (Engl). 2006 May 5. 119(9):789-92. [Medline].\nThobois S, Ballanger B, Xie-Brustolin J, Damier P, Durif F, Azulay JP, et al. Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia. J Cereb Blood Flow Metab. 2008 Jun. 28(6):1127-38. [Medline].\nGruber D, Trottenberg T, Kivi A, Schoenecker T, Kopp UA, Hoffmann KT, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology. 2009 Jul 7. 73(1):53-8. [Medline].\nGimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis. Acta Psychiatr Scand. 1985 May. 71(5):488-94. [Medline].\nVandel P, Bonin B, Leveque E, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997 Aug. 7(3):207-12. [Medline].\nGabellini AS, Pezzoli A, De Massis P, Sacquegna T. Veralipride-induced tardive dystonia in a patient with bipolar psychosis. Ital J Neurol Sci. 1992 Oct. 13(7):621-3. [Medline].\nChakrabarti S, Chand PK. Lithium - induced tardive dystonia. Neurol India. 2002 Dec. 50(4):473-5. [Medline].\nDaniel Schneider, MD, MA Assistant Professor of Neurology, Division of Movement Disorders and Behavioral Neurology, Medical Director for Neurologic and Psychiatric Deep Brain Stimulation, Rutgers Robert Wood Johnson Medical School\nPaula D Ravin, MD Associate Professor of Clinical Neurology, University of Massachusetts Memorial Health Care\nPaula D Ravin, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, Massachusetts Medical Society, American Headache Society, National Headache Foundation\nDisclosure: Received grant/research funds from Chelsea Pharmaceuticals for independent contractor; Received grant/research funds from Kyowa Pharma for independent contractor; Received consulting fee from Best Doctors Inc for consulting; Received grant/research funds from Beth Israel IRB for independent contractor.\nRandon S Welton, MD Associate Professor of Psychiatry, Director of Residency Training, Department of Psychiatry, Wright State University, Boonshoft School of Medicine\nRandon S Welton, MD is a member of the following medical societies: American Association of Directors of Psychiatric Residency Training, American Psychiatric Association, Dayton Psychiatric Association, Ohio Psychiatric Physicians Association\nAlan D Schmetzer, MD Professor Emeritus, Department of Psychiatry, Indiana University School of Medicine\nAlan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American Association for Physician Leadership, American Medical Association, American Psychiatric Association, International Society for ECT and Neurostimulation, American Neuropsychiatric Association\nThe authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Nestor Galvez-Jimenez, MD, and Perla Periut, MD, to the development and writing of this article.\nencoded search term (Tardive Dystonia) and Tardive Dystonia\nFast Five Quiz: Tardive Dyskinesia Differential Diagnosis\nFast Five Quiz: How Much Do You Know About Tardive Dyskinesia?\nPatient Simulation: Tardive Dyskinesia: Medication-Related Involuntary Orofacial Movements\nA 39-Year-Old Woman With Past Cocaine Use, Rash, and Seizure\nA 65-Year-Old Man Brought to the ED by Military Police\nNew Schizophrenia Treatment Guideline Released\nMost Vaccines Can Be Given Safely, Even After Reactions\nStrategies in Managing Tardive Dyskinesia: Intervention\nAccording to Neurologists\nCould RAS Dysfunction Explain COVID's Effects?\nInsomnia With Short Sleep Linked to Cognitive Impairment\nThe Cat’s Meow: Felines as Seizure Detectors?\nNeurologist as Patient: A Missed Diagnosis, Poor Communication, and Incompetent Care Could Have Led to Quadriplegia\nCannabis for Pain? An Expert's Guidance\nDiseases & Conditions Tardive Dyskinesia\nPatient Perspectives on Tardive Dyskinesia: A Review of Risk and Burden 0.75 CME / ABIM MOC Credits\n0.75 CME / ABIM MOC\nPatient Perspectives on Tardive Dyskinesia: A Review of Risk and Burden\n2010 /viewarticle/923959 Self Assessment\nSelf Assessment Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis\n2010 ingrezza-valbenazine-1000122 Drugs\nDrugs valbenazine"